{
  "docId": "019de074-abc1-773c-9c2f-d49993e7b79a",
  "docSlug": "59a1ae16b5e60c748be3b046cd750424",
  "documentTitle": "AstraZeneca | Investor Conference Presentation Deck | 20 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4138439,
  "pageNumber": 8,
  "pageCount": 20,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "executive_summary",
  "function": "frame_situation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a combination of technical explanation and a process diagram to define the technology.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-abc1-773c-9c2f-d49993e7b79a/8",
  "deckHref": "/decks/019de074-abc1-773c-9c2f-d49993e7b79a",
  "deckJsonHref": "/decks/019de074-abc1-773c-9c2f-d49993e7b79a.json",
  "deckAnchorHref": "/decks/019de074-abc1-773c-9c2f-d49993e7b79a#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.7,
        "y": 0.7
      },
      "kind": "callout",
      "text": "The strength of our emerging proprietary ADC technology is demonstrated with data across three assets",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8005b942-c973-45e2-ba06-0cdf03e308ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.6,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "diagram",
      "text": "How ADCs work: 3-step process diagram",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6bfe3f90-938a-4ca7-a329-b1daf0d5c4a4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.18,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "image",
      "text": "Diagram of ADC structure (Antibody, Linker, Payload)",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e22f2368-5c4c-414b-be1e-b70793f69d5a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.7,
        "y": 0.25
      },
      "kind": "list",
      "text": "Our vision is for ADCs to replace chemotherapy and become the backbone of cancer therapy. We are building on the success of Enhertu and the emerging promise of datopotamab deruxtecan.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0fadf1c-55c5-4d94-9dca-f2e46fcc5dba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.18,
        "x": 0.25,
        "y": 0.215
      },
      "kind": "paragraph",
      "text": "ADCs are targeted medicines that combine a monoclonal antibody (mAb), which binds to target proteins on the surface of cancer cells, with a drug, typically a cytotoxic chemotherapy agent, via a chemical linker.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96500e0d-9d14-424f-8695-592b97ce4a26",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "Overview and approach",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4b60702-69b6-4d09-918e-ba0d85d78e8c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 7,
      "beatId": "56cdd0e4-2e0f-4301-9ad2-c8da972ed7de",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Details on novel treatments and pipeline advancements aim to satisfy the need with solutions.",
      "position": 3,
      "confidence": 0.7,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 7,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "3287b1c0-2747-4dd0-ac7f-c89f27fd4924",
      "evidence": "The focus on proprietary ADC technology and pipeline advancements.",
      "position": 1,
      "objective": "How can AstraZeneca deliver innovative treatments for resectable lung cancer and other solid tumors?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}